At a glance
ClinicalIndex Comparison RecordN/ACompleted· 51 enrolled
Drug / intervention
Intranasal Oxytocindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Target Engagement for Oxytocin: Response to 8 Doses
In Brief
A clinical study evaluating Intranasal Oxytocin for Schizophrenia Spectrum. Completed, enrolled 51 participants.
Detailed Summary
This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two proposed measures of target engagement in brain. The targets are (1) the suppression of a particular wave form (mu) on the electroencephalogram (EEG) while subjects observe a socially relevant form of motion and (2) pupil dilation will subjects identify faces showing different emotions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia Spectrum
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionJul 2017
TodayJul 2026
First PostedJul 15, 2015
Enrollment StartSep 1, 2015
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.0 years ago
Interventions
Intranasal Oxytocindrug